Trial · NCT01453049
Results by group150
Each measurement the trial posted, group by group, in the words and numbers it posted.
61 to 80 of 150
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) at Week 24/EW | Rosiglitazone+Glimepiride FDC | 0.0584 | Standard Deviation 0.1903 | scores on a scale | |
| Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) at Week 24/EW | Glimepiride | 0.0447 | Standard Deviation 0.1504 | scores on a scale | |
| Change From Baseline in Adjusted Diabetes Quality of Life (A-DQOL) Scores at Week 24/EW | Rosiglitazone+Glimepiride FDC | -7.0 | Standard Deviation 11.10 | scores on a scale | |
| Change From Baseline in Adjusted Diabetes Quality of Life (A-DQOL) Scores at Week 24/EW | Glimepiride | -0.1 | Standard Deviation 18.63 | scores on a scale | |
| Number of Participants With Hypoglycemic Events | Rosiglitazone+Glimepiride FDC | All participants with any hypoglycemic events (HE) | 8 | participants | |
| Number of Participants With Hypoglycemic Events | Glimepiride | All participants with any hypoglycemic events (HE) | 7 | participants | |
| Number of Participants With Hypoglycemic Events | Rosiglitazone+Glimepiride FDC | HbA1c responders with any HEs | 7 | participants | |
| Number of Participants With Hypoglycemic Events | Glimepiride | HbA1c responders with any HEs | 6 | participants | |
| Number of Participants With Hypoglycemic Events | Rosiglitazone+Glimepiride FDC | FPG responders with any HEs | 5 | participants | |
| Number of Participants With Hypoglycemic Events | Glimepiride | FPG responders with any HEs | 0 | participants | |
| Number of Hypoglycemic Events | Rosiglitazone+Glimepiride FDC | HE for all participants | 13 | Hypoglycemic events | |
| Number of Hypoglycemic Events | Glimepiride | HE for all participants | 11 | Hypoglycemic events | |
| Number of Hypoglycemic Events | Rosiglitazone+Glimepiride FDC | HE for HbA1c responders | 12 | Hypoglycemic events | |
| Number of Hypoglycemic Events | Glimepiride | HE for HbA1c responders | 10 | Hypoglycemic events | |
| Number of Hypoglycemic Events | Rosiglitazone+Glimepiride FDC | HE for FPG responders | 9 | Hypoglycemic events | |
| Number of Hypoglycemic Events | Glimepiride | HE for FPG responders | 0 | Hypoglycemic events | |
| Number of Participants With a Bone Fracture | Rosiglitazone+Glimepiride FDC | 0 | participants | ||
| Number of Participants With a Bone Fracture | Glimepiride | 0 | participants | ||
| Change From Baseline in White Blood Cell (WBC) Count and Platelet Count at Week 24/EW | Rosiglitazone+Glimepiride FDC | WBC count | -0.418 | Standard Deviation 0.9091 | Giga per liter (10^9/L) cells |
| Change From Baseline in White Blood Cell (WBC) Count and Platelet Count at Week 24/EW | Glimepiride | WBC count | 0.148 | Standard Deviation 0.8855 | Giga per liter (10^9/L) cells |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01453049/results?page=4